Is mitotane a targeted drug or a chemotherapy drug?

Mitotane (Mitotane) is actually not a typical targeted drug, but more similar to a traditional chemotherapy drug. Targeted drugs are usually designed to specifically act on certain molecules or pathways in cancer cells, thereby more precisely inhibiting tumor growth and spread without causing significant damage to normal cells. In contrast, Mitotane's mechanism of action does not target specific cancer cell molecules, but inhibits the proliferation and spread of cancer cells by affecting the function of adrenocortical cells.

Mitotane belongs to a class of drugs called lipase inducers (adrenocorticolytic agent ), which mainly act on adrenocortical cells, especially chromaffin cells of the adrenal cortex. Its mechanisms include inhibiting the ability of adrenocortical cells to produce corticosteroids and directly destroying these cells, thereby inhibiting the growth and spread of cancer cells.

Althoughmitotaneis not a typical targeted drug, in some cases it can still be classified as part of a targeted therapy. Especially in the treatment of adrenocortical cancer, where understanding of the disease is still limited, mitotane is sometimes classified as a partially targeted therapy because it targets specific types of adrenocortical cells.

It should be noted that Mitotane may produce more side effects than typical targeted drugs because it has a broad impact on adrenocortical cells, not only affecting cancer cells but may also affect normal adrenal function. Therefore, when using mitotane, doctors need to carefully monitor the patient's condition and response and adjust the treatment plan based on the specific situation.